MA39899A - Utilisation de sécoïsolaricirésinol diglucosides (sdg) et composés associés pour la protection contre le rayonnement et les dommages chimiques - Google Patents

Utilisation de sécoïsolaricirésinol diglucosides (sdg) et composés associés pour la protection contre le rayonnement et les dommages chimiques

Info

Publication number
MA39899A
MA39899A MA039899A MA39899A MA39899A MA 39899 A MA39899 A MA 39899A MA 039899 A MA039899 A MA 039899A MA 39899 A MA39899 A MA 39899A MA 39899 A MA39899 A MA 39899A
Authority
MA
Morocco
Prior art keywords
sdg
protection against
related compounds
chemical damage
against radiation
Prior art date
Application number
MA039899A
Other languages
English (en)
French (fr)
Inventor
Melpo Christofidou-Solomidou
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MA39899A publication Critical patent/MA39899A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MA039899A 2014-05-30 2015-06-01 Utilisation de sécoïsolaricirésinol diglucosides (sdg) et composés associés pour la protection contre le rayonnement et les dommages chimiques MA39899A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462005330P 2014-05-30 2014-05-30
US201562101296P 2015-01-08 2015-01-08

Publications (1)

Publication Number Publication Date
MA39899A true MA39899A (fr) 2021-05-26

Family

ID=54700083

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039899A MA39899A (fr) 2014-05-30 2015-06-01 Utilisation de sécoïsolaricirésinol diglucosides (sdg) et composés associés pour la protection contre le rayonnement et les dommages chimiques

Country Status (9)

Country Link
EP (1) EP3148560A4 (enExample)
JP (2) JP2017520620A (enExample)
KR (1) KR20170010019A (enExample)
CN (2) CN112336736A (enExample)
AU (2) AU2015266614A1 (enExample)
CA (1) CA2950744A1 (enExample)
IL (1) IL249219A0 (enExample)
MA (1) MA39899A (enExample)
WO (1) WO2015184441A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071746B2 (en) 2016-06-07 2021-07-27 The Trustees Of The University Of Pennsylvania Compositions and methods for protecting organs from ischemia/reperfusion injury associated with transplantation
CA3211208A1 (en) * 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
US20210128596A1 (en) * 2017-09-27 2021-05-06 University Of Pennsylvania Compositions and methods for treating septic cardiomyopathy
EP3687545A4 (en) * 2017-09-27 2021-06-09 The Trustees Of The University Of Pennsylvania USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION-INDUCED CARDIOVASCULAR DYSFUNCTION
CN112601462B (zh) * 2018-08-31 2023-10-31 伊诺弗斯公司 植物抗氧化剂
CN116850162A (zh) * 2023-08-08 2023-10-10 南通大学附属医院 肠二醇在制备治疗放射性肠炎药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312164C (en) * 1999-06-30 2009-12-15 University Of Saskatchewan Technologies Inc. Antioxidant activity in sdg metabolites
WO2001095901A1 (en) * 2000-06-14 2001-12-20 Alla Shapiro Radioprotective agents
CN100365005C (zh) * 2006-03-02 2008-01-30 江南大学 一种从亚麻籽中提取纯化开环异落叶松树脂酚二葡萄糖苷的方法
US20070293458A1 (en) * 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage
US10449224B2 (en) * 2007-05-25 2019-10-22 The Trustees Of The University Of Pennsylvania Flaxseed lignan complex, methods of using and compositions thereof
WO2010017332A2 (en) * 2008-08-07 2010-02-11 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Radioprotectants targeting thrombospondin-1 and cd47
CN101759731B (zh) * 2008-12-25 2011-10-19 中国科学院兰州化学物理研究所 亚麻籽胶和开环异落叶松树脂酚二葡萄糖苷的提取方法
SI3007557T1 (sl) * 2013-06-10 2018-12-31 The Trusees Of The University Of Pennsylvania Priprava (S,S)-sekoizolariciresinol diglukozida in (R,R)-sekoizolariciresinol diglukozida

Also Published As

Publication number Publication date
IL249219A0 (en) 2017-02-28
EP3148560A4 (en) 2018-04-25
CA2950744A1 (en) 2015-12-03
JP2017520620A (ja) 2017-07-27
AU2015266614A1 (en) 2016-12-15
JP2020121987A (ja) 2020-08-13
AU2020270469A1 (en) 2020-12-17
CN107155304A (zh) 2017-09-12
KR20170010019A (ko) 2017-01-25
WO2015184441A9 (en) 2016-01-21
WO2015184441A2 (en) 2015-12-03
WO2015184441A3 (en) 2016-03-10
EP3148560A2 (en) 2017-04-05
CN112336736A (zh) 2021-02-09

Similar Documents

Publication Publication Date Title
GB2558826B (en) Mitigation of anti-sandbox malware techniques
EP3474845A4 (en) Immunomodulatory connections
EP2969770A4 (en) CLOSING GUARD
DK3119762T3 (da) Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
EP3161714A4 (en) Mitigation of malware
DK3256853T3 (da) Forudsigelse af t-celleepitoper, der er egnede til vaccination
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
MA46373A (fr) Composés utilisés comme modulateurs de ror gamma
DK3148529T3 (da) Forbindelser til behandling af hjernecancer
DK3160927T3 (da) Fremgangsmåde til fremstilling af ethylenglycol ud fra sukker
KR20180084990A (ko) 프로펜의 에폭시화를 위한 방법 및 반응기
DK3180329T3 (da) Triazoler som nr2b receptorinhibitorer
PL3288532T3 (pl) Polimery do stabilizacji związków nadtlenkowych
HUE058257T2 (hu) Eljárások oxatiazin-jellegû vegyületek elõállítására
MA39899A (fr) Utilisation de sécoïsolaricirésinol diglucosides (sdg) et composés associés pour la protection contre le rayonnement et les dommages chimiques
PL3400269T3 (pl) Zastosowanie 4-bora-3a,4a-diaza-s-indacenów do zabezpieczania
DK3360117T3 (da) Fremgangsmåde til overvågning af overensstemmelse af personligt sikkerhedsudstyr
HUE054271T2 (hu) Mielóma Multiplex (MM) kezelése
EP3314509A4 (en) Mitigation of malware
MA49623A (fr) Composés chimiques
EP3337804A4 (en) BIOKON JUGATE OF HETEROCYCLIC COMPOUNDS
HUE042043T2 (hu) Malária megelõzésére vagy kezelésére alkalmas triaminopiridin-vegyületek
HUE045704T2 (hu) Eljárás 5-fluor-1H-pirazolok elõállítására hexafluorpropénbõl kiindulva
GB2543602B (en) Mitigation of anti-sandbox malware techniques
PL4012035T3 (pl) Wektory wirusowe związane z adenowirusami do leczenia jaskry miocylinowej (myoc)